{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of OX40 when administered intravenously in combination with belantamab mafodotin.","groups":[{"description":"Participants with RRMM received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles.","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8mg OX40"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion as powder for solution Q3W infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin EOI on day 1 of 21-day cycles.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8mg OX40"}],"populationDescription":"Pharmacokinetic population included all participants in the safety population from whom at least one PK sample has been obtained and analysed.\n\nNo participants were enrolled in CE Phase as study got terminated.","reportingStatus":"POSTED","timeFrame":"Up to Day 1 (End of Infusion) of Cycle 6 (Each Cycle consist of 21 days)","title":"CE Phase: OX40 Concentration When Administered in Combination With Belantamab Mafodotin","type":"SECONDARY"}